Fundraising Fox

Carlo Rizzuto

Investor

Managing Director at Versant Ventures

New York, New York

Writes $100K – $5M checks · typically $1.5M

About

Carlo Rizzuto, a PhD virologist-turned-VC who pioneered and championed epitranscriptomics and backed Gotham Therapeutics early, is a hands-on builder who often serves as acting CEO/CBO to create first-wave biology companies.

Invests in

BiotechHealthtechMedical Devices

Experience

  1. Versant VenturesManaging Directorcurrent2022 — presentNew York, New York, United States
  2. Versant VenturesPartner2012 — 2022New York City Metropolitan Area
  3. Highline TherapeuticsCEO2015 — 2022New York City Metropolitan Area
  4. NovartisGlobal Program Team Director2010 — 2012
  5. Novartis International AGAssistant to the CEO2010
  6. NovartisAssistant to CEO - Pharmaceuticals2009 — 2010
  7. McKinsey & CompanyAssociate Principal2002 — 2008
  8. engeneOSBusiness Development Manager2000 — 2002

Education

  1. Harvard UniversityPhD, Virology1993 — 1999
  2. University of VirginiaBA, Biology1988 — 1992
  3. Miller Place High School

Skills & more

Strategy35Strategic Planning14Pharmaceutical Industry65Lifesciences16Medical Devices27Business Strategy19Management Consulting13Product Development5Biotechnology31R&D8Marketing Strategy9Business Planning6
+6 moreMolecular BiologyVenture CapitalDrug DevelopmentBusiness DevelopmentCross-functional Team LeadershipLife Sciences

From Carlo's professional profile.

Same school

Shared employers

Deals · 8

Nexo Therapeutics, Inc.Board seat

via Versant Ventures · filed Mar 2026 · $60M raise

Pep2Tango TherapeuticsBoard seat

via Versant Ventures · filed Nov 2024 · $16.7M raise

Jnana Therapeutics Inc.Board seat

via Versant Ventures · filed Jan 2024 · $107M raise

858 Therapeutics, Inc.Board seat

via Versant Ventures · filed May 2021 · $40M raise

Graphite Bio, Inc.Board seat

via Versant Ventures · filed Mar 2021 · $150.7M raise

Century Therapeutics, Inc.Board seat

via Versant Ventures · filed Mar 2021 · $160M raise

Pandion Therapeutics HoldcoBoard seat

via Versant Ventures · filed Apr 2020 · $80M raise

Pandion TherapeuticsBoard seat

via Versant Ventures · filed Jan 2018 · $57.6M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Versant Ventures

Network7

Investors connected to Carlo in public investor directories — a warm-intro map.